ones been grieve Thanks, world. we to Michael. heroic on to The disrupted. see times. of of this are pandemic. as Vertex’s who have that is has has for honor call. world the tough fighting and welcome significant the around every loved been we people the lives new country a by with CEO These the those those We being challenge around the you done and people salute an We frontlines and in lost work know conference President pandemic the It COVID-XX
future approved with of world treat treat company the outside unique company I exactly medicines, can CF and a broad late with X and innovator modalities you a extraordinarily with I using stage with TRIKAFTA, current company, pandemic, is top Acknowledging a of a want that forward. want CF leadership going believe high around serial diverse In a a record, a company a serious a with patients Vertex part track sheet; ways, Vertex of ever. diseases for in a many workforce; short, future difficult and XX% efficacy; we company bottom and strong by a growth remains telling cure that a be of this multiple finally, potentially including proven the line talented to of up the inclusive time why the to preclinical a company is everyone, and pipeline we CF; balance begin believe medicine an senior clinical despite and kind with brighter and team to to than as
of I’m enabled patients. science At challenges my Since witnessed core, deep scientist interest in and by a the ingenuity this driven and physician I tackle to of Vertex, to medicines. medicine company unprecedented a commercialization that joining new discovery, the have passion drive in and advance have development
advancement development to hard already was the TRIKAFTA program our rapid example, in XXXX. approval majority research believe, that of the for patients original true U.S. but combination PDUFA our triple through early date eligible the and on XX, TRIKAFTA. in are of U.S. For and March the the Today, It’s
pioneering Another the company. gene-editing leading like the beta partners potentially CRISPR and have to of in example use to of thalassemia. cure diseases this with sickle am humbled is our I Jeff Therapeutics, unique at follow opportunity CRISPR cell
financial results business, to today, stronger in our announced performance. ever. our as first quarter Now, on demonstrated is Vertex’s QX than record
last the in product SYMKEVI of launch of the ORKAMBI U.S. successful and XX% to growth driven revenues and year the to highly billion, QX U.S. CF Our $X.XX compared TRIKAFTA are the by up outside
operating Our million. non-GAAP rose to $XXX XXX% income
also while to continue we and working is grow investing revenues innovation. significantly strategy in our Our and earnings,
growth CF future, continued several the look in to we franchise confident are of we for the reasons. As our
possible. as addressing serve. CF And the patient are cause efforts by populations they changing important an lives of they healthy First, our the patients’ are of remain underlying the disease, of part as medicines to
for to robust distribute the CF our long our ability our to the in supply chain manufacture and our to we uninterrupted continue world to confident and supply term. medicines medicines Second, is patients remain around
more while our course the and next triple the the and securing to regimen unpredictable, well into a line approval in site we CF retain around leadership the the combination decade. groups and younger of launching sustaining age pandemic Finally, countries of is clear world in
be been Our and remains CF to treat has much patients for able vision TRIKAFTA XX% all to very vision of intact. that
of a the in the billion. of performance to the strong will our review and guidance to Given we are our a $X.X factors for our products year new revenue Stuart few CF raising QX, moments. Charlie guidance in billion range underlying $X.X
patients to specific to and pipeline discuss turn progress are programs we continue our actions and protecting how now me taking providers. Let healthcare clinical while to our
each see, program different. will you unique somewhat and is As
studies on regulatory working have our can our they to our clinical successfully. that ensure adapt submissions ongoing completed teams and as and be track been needed First, stay development diligently regulators to with to to
continue CF to make in We our trials. progress ongoing
for For our the as our Europe submission the have infants X down well Similarly, CF as U.S. X team a to age. months example, in the CF to completed KALYDECO EMA in the regulatory program. with of we been of progress able sNDA to FSGS variation for Type
been diseases VX-XXX past for FSGS. And APOLX-mediated open. clinical study have program APOLX-mediated in Our our few able Phase weeks XX of the team sites X to in have kidney initiate we our now
study treatment in clinical X and other to program. each AAT need system the clinical ongoing VX-XXX including temporarily and where the resources they we every our enrollment healthcare closely need to analyzed the keep hand, different have some the On the needed and and safe we preserve paused is are recently of to in then made most. decisions for program studies of study Every Phase have respect on patients the situation based or
preclinical are do addition we forward, our is it clinical in so when maintain momentum to our to our facilities, have programs activities our are stayed reduced that we and and so, the open that have next on-site possible our we we our development. labs IND-enabling late-stage studies. occupancy first-in-human to at protect progress, move research sites entering have employees Though can working In into prioritized medicines to for
to X continue of clinical type we therapy XXXX in global starting This or program have in XXXX. our includes development early patients a late cell diabetes, where for
we investing external supports in with novel innovation. of therapies development business discovery in This are of capsids This of We new the and collaboration strategy Therapeutics. to development for continuing week disease announced Affinia AAV number a also delivery in genetic progress a and collaboration vivo our areas.
We are therapy to into the cell building. that are pleased toolbox bring this and capability we gene
pandemic, hires we Finally, new grow team despite QX. leadership with important the continue promotions our senior to and in several
Carmen Bozic, is The to Chief earlier Medical this first promoted Dr. is month. Officer who
joined development, from oversaw Biogen, including and extensive development X has medicines and important the has now regulatory in where clinical biometrics medical Carmen approval affairs, related for experience Vertex functions. development XXXX safety, and she Spinraza. other Carmen clinical clinical drug and operations, responsibility global Tecfidera drug of in
who Sanna we where was when in The CEO. joined second Vertex he acquired is XXXX, Bastiano Semma Dr.
all Vertex. We Therapies role, leads have role he as Chief X gene this cell disease, he technologies cell our type thalassemia, expanded for Bastiano’s well therapy and now others. diabetes DMD, beta sickle at related In and as therapy and Cell new gene-editing, is Genetic of of programs, and
cell that and that and absolutely I am us at I has roles build Bastiano on enable and experience Carmen skill-set are in confident his to delighted Vertex extensive at and Magenta genetic capabilities to therapies will am have Novartis. to And Bastiano prior second the from none. expertise team.
time this find which ourselves we pass. in now In will summary, in right moment extraordinary
to to Despite together. this positioned through get of and all continue revenues is well transformative our grow advanced CF these unusual will Vertex areas earnings, our circumstances, medicines in CF. serve and disease We pipeline patients, beyond
it Stuart. turn over to me Let
